Short Interest Worth Watching: Contravir Pharmaceuticals Incorporated (NASDAQ:CTRV) on Focus After Report of More Shorts

November 30, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Worth Watching: Contravir Pharmaceuticals Incorporated (NASDAQ:CTRV) on Focus After Report of More Shorts

The stock of Contravir Pharmaceuticals Incorporated (NASDAQ:CTRV) registered an increase of 127.26% in short interest. CTRV’s total short interest was 3.19M shares in November as published by FINRA. Its up 127.26% from 1.41M shares, reported previously. With 5.08 million shares average volume, it will take short sellers 1 days to cover their CTRV’s short positions. The short interest to Contravir Pharmaceuticals Incorporated’s float is 6.6%. About 362,648 shares traded hands. ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has risen 98.10% since April 27, 2016 and is uptrending. It has outperformed by 92.87% the S&P500.

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $119.61 million. The Firm focuses on the development of antiviral drugs for the treatment of Hepatitis B virus infections. It currently has negative earnings. The Firm develops a range of compounds to treat HBV infection, which include CMX157 and CRV431.

CTRV Company Profile

ContraVir Pharmaceuticals, Inc., incorporated on May 15, 2013, is a biopharmaceutical company. The Firm focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Firm develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Firm is also developing an antiviral asset, FV-100.

More news for ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) were recently published by: Prnewswire.com, which released: “ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors” on September 21, 2016. Prnewswire.com‘s article titled: “ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer” and published on March 31, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>